Clinical Trials Search
Clinical Trial 18664
Cancer Type: Malignant Hematology
Interventions:Alkeran (Melphalan); Carmustine; Cytarabine (Cytosine Arabinoside); FK228 (Romidepsin); Melphalan; Romidepsin; etoposide
Study Type: Treatment
Phase of Study: Phase II
- Farhad Khimani
A Phase 2, Multi-Center Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin for the Treatment of T cell Non-Hodgkin's Lymphoma
The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.
Primary aim is to determine a preliminary estimate of the progression-free survival (PFS) of patients with T cell Non-Hodgkin's Lymphoma (T NHL) who receive maintenance Romidepsin at 2 years post-transplant for patients transplanted in CR1 or PR1 with standard risk histologies. Secondary: Determine PFS at 2 years for patients transplanted in >/= CR/PR2 or for patients with high risk histologies. Determine the toxicities associated with Romidepsin in following autologous transplantation. Determine the probability of Overall Survival (OS) at 2 years post transplant for all patients undergoing transplant. Characterize the effect of Romidepsin on immune recovery post HDT-ASCT. OS and PFS 1 year after Romidepsin completion.